A Randomized, Open-Label Study of the Effect of PEGASYS Plus COPEGUS With or Without Concomitant Pioglitazone (Actos) on Early Viral Kinetics in Treatment-Naive Patients With Chronic Hepatitis C, Genotype-1, and Insulin Resistance.

Trial Profile

A Randomized, Open-Label Study of the Effect of PEGASYS Plus COPEGUS With or Without Concomitant Pioglitazone (Actos) on Early Viral Kinetics in Treatment-Naive Patients With Chronic Hepatitis C, Genotype-1, and Insulin Resistance.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2012

At a glance

  • Drugs Peginterferon alfa-2a; Pioglitazone; Ribavirin
  • Indications Hepatitis C; Insulin resistance
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Jul 2011 NCT reports actual patient number as 154.
    • 15 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top